Researchers are excitedly investigating retatrutide, a innovative medication developed by Eli Lilly, as a potential step in physique loss . Unlike many existing approaches, retatrutide is a twin-action receptor targeting both GLP-1 and GIP, hormones that affect appetite and blood glucose balance.